Targeting USP47 enhances the efficacy of KRAS inhibitor in KRASG12C mutated non-small cell lung cancer by controlling deubiquitination of c-Myc
FDA-approved KRASG12C inhibitors, like Sotorasib, target G12C-mutated KRAS in NSCLC. However, issues with insensitivity and drug resistance have emerged, requiring the development of new combination therapies to overcome these limitations. USP47 has been identified as a regulator of cancer-related s...
Salvato in:
| Autori principali: | , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Elsevier
2025-05-01
|
| Serie: | Pharmacological Research |
| Soggetti: | |
| Accesso online: | http://www.sciencedirect.com/science/article/pii/S1043661825001471 |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|